 |
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Previous Article | Next Article
The Journal of Neuroscience, November 15, 2000, 20(22):8620-8628
Hypothalamic Arousal Regions Are Activated during Modafinil-Induced Wakefulness
Thomas E. Scammell1, Ivy V. Estabrooke1, Marie T. McCarthy1, Richard M. Chemelli2, Masashi Yanagisawa2, Matthew S. Miller3, and Clifford B. Saper1, 4 1 Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, 2 Department of Molecular Genetics, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, 3 Cephalon, Inc., West Chester, Pennsylvania, and 4 Program in Neuroscience, Harvard Medical School, Boston, Massachusetts
Modafinil is an increasingly popular wake-promoting drug used for the treatment of narcolepsy, but its precise mechanism of action is unknown. To determine potential pathways via which modafinil acts, we administered a range of doses of modafinil to rats, recorded sleep/wake activity, and studied the pattern of neuronal activation using Fos immunohistochemistry. To contrast modafinil-induced wakefulness with spontaneous wakefulness, we administered modafinil at midnight, during the normal waking period of rats. To determine the influence of circadian phase or ambient light, we also injected modafinil at noon on a normal light/dark cycle or in constant darkness. We found that 75 mg/kg modafinil increased Fos immunoreactivity in the tuberomammillary nucleus (TMN) and in orexin (hypocretin) neurons of the perifornical area, two cell groups implicated in the regulation of wakefulness. This low dose of modafinil also increased the number of Fos-immunoreactive (Fos-IR) neurons in the lateral subdivision of the central nucleus of the amygdala. Higher doses increased the number of Fos-IR neurons in the striatum and cingulate cortex. In contrast to previous studies, modafinil did not produce statistically significant increases in Fos expression in either the suprachiasmatic nucleus or the anterior hypothalamic area. These observations suggest that modafinil may promote waking via activation of TMN and orexin neurons, two regions implicated in the promotion of normal wakefulness. Selective pharmacological activation of these hypothalamic regions may represent a novel approach to inducing wakefulness.
Key words: modafinil; tuberomammillary nucleus; lateral hypothalamic area; perifornical area; orexin; hypocretin; striatum; amygdala; suprachiasmatic nucleus; anterior hypothalamic area; Fos; dopamine; stimulant; narcolepsy
Copyright © 2000 Society for Neuroscience 0270-6474/00/20228620-09$05.00/0
This article has been cited by other articles:
A Spathis, R Dhillan, D Booden, K Forbes, K Vrotsou, and K Fife
Modafinil for the treatment of fatigue in lung cancer: a pilot study
Palliative Medicine, June 1, 2009; 23(4): 325 - 331.
[Abstract] [PDF]
N. D. Volkow, J. S. Fowler, J. Logan, D. Alexoff, W. Zhu, F. Telang, G.-J. Wang, M. Jayne, J. M. Hooker, C. Wong, et al.
Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain: Clinical Implications
JAMA, March 18, 2009; 301(11): 1148 - 1154.
[Abstract] [Full Text] [PDF]
Y. Rao, M. Lu, F. Ge, D. J. Marsh, S. Qian, A. H. Wang, M. R. Picciotto, and X.-B. Gao
Regulation of Synaptic Efficacy in Hypocretin/Orexin-Containing Neurons by Melanin Concentrating Hormone in the Lateral Hypothalamus
J. Neurosci., September 10, 2008; 28(37): 9101 - 9110.
[Abstract] [Full Text] [PDF]
W.-M. Qu, Z.-L. Huang, X.-H. Xu, N. Matsumoto, and Y. Urade
Dopaminergic D1 and D2 Receptors Are Essential for the Arousal Effect of Modafinil
J. Neurosci., August 20, 2008; 28(34): 8462 - 8469.
[Abstract] [Full Text] [PDF]
H. L. Haas, O. A. Sergeeva, and O. Selbach
Histamine in the Nervous System
Physiol Rev, July 1, 2008; 88(3): 1183 - 1241.
[Abstract] [Full Text] [PDF]
M. B. Kelz, Y. Sun, J. Chen, Q. Cheng Meng, J. T. Moore, S. C. Veasey, S. Dixon, M. Thornton, H. Funato, and M. Yanagisawa
An essential role for orexins in emergence from general anesthesia
PNAS, January 29, 2008; 105(4): 1309 - 1314.
[Abstract] [Full Text] [PDF]
S. Morein-Zamir, D. C. Turner, and B. J. Sahakian
A Review of the Effects of Modafinil on Cognition in Schizophrenia
Schizophr Bull, November 1, 2007; 33(6): 1298 - 1306.
[Abstract] [Full Text] [PDF]
A. Y. Deutch and M. Bubser
The Orexins/Hypocretins and Schizophrenia
Schizophr Bull, November 1, 2007; 33(6): 1277 - 1283.
[Abstract] [Full Text] [PDF]
R. H. Belmaker
Modafinil Add-On in the Treatment of Bipolar Depression
Am J Psychiatry, August 1, 2007; 164(8): 1143 - 1145.
[Full Text] [PDF]
F. J. Urbano, E. Leznik, and R. R. Llinas
Modafinil enhances thalamocortical activity by increasing neuronal electrotonic coupling
PNAS, July 24, 2007; 104(30): 12554 - 12559.
[Abstract] [Full Text] [PDF]
I. C. Webb, M. S. Pollock, and R. E. Mistlberger
Modafinil [2-[(Diphenylmethyl)sulfinyl]acetamide] and Circadian Rhythms in Syrian Hamsters: Assessment of the Chronobiotic Potential of a Novel Alerting Compound
J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 882 - 889.
[Abstract] [Full Text] [PDF]
C. DeBattista
Augmentation and combination strategies for depression
J Psychopharmacol, May 1, 2006; 20(3_suppl): 11 - 18.
[Abstract] [PDF]
J. Lu, T. C. Jhou, and C. B. Saper
Identification of Wake-Active Dopaminergic Neurons in the Ventral Periaqueductal Gray Matter
J. Neurosci., January 4, 2006; 26(1): 193 - 202.
[Abstract] [Full Text] [PDF]
W G Ondo, R Fayle, F Atassi, and J Jankovic
Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial
J. Neurol. Neurosurg. Psychiatry, December 1, 2005; 76(12): 1636 - 1639.
[Abstract] [Full Text] [PDF]
J. Biederman, J. M. Swanson, S. B. Wigal, C. J. Kratochvil, S. W. Boellner, C. Q. Earl, J. Jiang, and L. Greenhill
Efficacy and Safety of Modafinil Film-Coated Tablets in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study
Pediatrics, December 1, 2005; 116(6): e777 - e784.
[Abstract] [Full Text] [PDF]
J. R.L. Schwartz, N. T. Feldman, and R. K. Bogan
Dose Effects of Modafinil in Sustaining Wakefulness in Narcolepsy Patients With Residual Evening Sleepiness
J Neuropsychiatry Clin Neurosci, August 1, 2005; 17(3): 405 - 412.
[Abstract] [Full Text] [PDF]
S. A. SPENCE, R. D. GREEN, I. D. WILKINSON, and M. D. HUNTER
Modafinil modulates anterior cingulate function in chronic schizophrenia
The British Journal of Psychiatry, July 1, 2005; 187(1): 55 - 61.
[Abstract] [Full Text] [PDF]
B. Stankoff, E. Waubant, C. Confavreux, G. Edan, M. Debouverie, L. Rumbach, T. Moreau, J. Pelletier, C. Lubetzki, M. Clanet, et al.
Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study
Neurology, April 12, 2005; 64(7): 1139 - 1143.
[Abstract] [Full Text] [PDF]
K R Kaufman and R Gerner
Modafinil in sports: ethical considerations
Br. J. Sports Med., April 1, 2005; 39(4): 241 - 244.
[Abstract] [Full Text] [PDF]
K. A. Waters, K. E. Burnham, D. O'Connor, G. R. Dawson, and R. Dias
Assessment of modafinil on attentional processes in a five-choice serial reaction time test in the rat
J Psychopharmacol, March 1, 2005; 19(2): 149 - 158.
[Abstract] [PDF]
P. P Fernandes and F. Petty
Modafinil for Remitted Bipolar Depression with Hypersomnia
Ann. Pharmacother., December 1, 2003; 37(12): 1807 - 1809.
[Abstract] [Full Text] [PDF]
R. Bakshi
Fatigue associated with multiple sclerosis: diagnosis, impact and management
Multiple Sclerosis, June 1, 2003; 9(3): 219 - 227.
[Abstract] [PDF]
H. Zheng, M. Corkern, I. Stoyanova, L. M. Patterson, R. Tian, and H.-R. Berthoud
Peptides that Regulate Food Intake: Appetite-inducing accumbens manipulation activates hypothalamic orexin neurons and inhibits POMC neurons
Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2003; 284(6): R1436 - R1444.
[Abstract] [Full Text] [PDF]
J. R. MacDonald, J. D. Hill, and M. A. Tarnopolsky
Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy
Neurology, December 24, 2002; 59(12): 1876 - 1880.
[Abstract] [Full Text] [PDF]
J. P. Kukkonen, T. Holmqvist, S. Ammoun, and K. E. O. Akerman
Functions of the orexinergic/hypocretinergic system
Am J Physiol Cell Physiol, December 1, 2002; 283(6): C1567 - C1591.
[Abstract] [Full Text] [PDF]
H. Zheng, M. M. Corkern, S. M. Crousillac, L. M. Patterson, C. B. Phifer, and H.-R. Berthoud
Neurochemical phenotype of hypothalamic neurons showing Fos expression 23 h after intracranial AgRP
Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2002; 282(6): R1773 - R1781.
[Abstract] [Full Text] [PDF]
H. STERNBACH
Adjunctive Modafinil in ALS
J Neuropsychiatry Clin Neurosci, May 1, 2002; 14(2): 239 - 239.
[Full Text] [PDF]
O. Hayaishi
Functional Genomics of Sleep and Circadian Rhythm: Invited Review: Molecular genetic studies on sleep-wake regulation, with special emphasis on the prostaglandin D2 system
J Appl Physiol, February 1, 2002; 92(2): 863 - 868.
[Abstract] [Full Text] [PDF]
M. N. Alam, H. Gong, T. Alam, R. Jaganath, D. McGinty, and R. Szymusiak
Sleep-waking discharge patterns of neurons recorded in the rat perifornical lateral hypothalamic area
J. Physiol., January 15, 2002; 538(2): 619 - 631.
[Abstract] [Full Text] [PDF]
I O Ebrahim, R S Howard, M D Kopelman, M K Sharief, and A J Williams
The hypocretin/orexin system
J R Soc Med, January 5, 2002; 95(5): 227 - 230.
[Full Text] [PDF]
K. S. Eriksson, O. Sergeeva, R. E. Brown, and H. L. Haas
Orexin/Hypocretin Excites the Histaminergic Neurons of the Tuberomammillary Nucleus
J. Neurosci., December 1, 2001; 21(23): 9273 - 9279.
[Abstract] [Full Text] [PDF]
C. Guilleminault and S. N. Brooks
Excessive daytime sleepiness: A challenge for the practising neurologist
Brain, August 1, 2001; 124(8): 1482 - 1491.
[Abstract] [Full Text] [PDF]
Z.-L. Huang, W.-M. Qu, W.-D. Li, T. Mochizuki, N. Eguchi, T. Watanabe, Y. Urade, and O. Hayaishi
Arousal effect of orexin A depends on activation of the histaminergic system
PNAS, August 1, 2001; (2001) 181330998.
[Abstract] [Full Text] [PDF]
I. V. Estabrooke, M. T. McCarthy, E. Ko, T. C. Chou, R. M. Chemelli, M. Yanagisawa, C. B. Saper, and T. E. Scammell
Fos Expression in Orexin Neurons Varies with Behavioral State
J. Neurosci., March 1, 2001; 21(5): 1656 - 1662.
[Abstract] [Full Text] [PDF]
Z.-L. Huang, W.-M. Qu, W.-D. Li, T. Mochizuki, N. Eguchi, T. Watanabe, Y. Urade, and O. Hayaishi
Arousal effect of orexin A depends on activation of the histaminergic system
PNAS, August 14, 2001; 98(17): 9965 - 9970.
[Abstract] [Full Text] [PDF]
T. C. Chou, C. E. Lee, J. Lu, J. K. Elmquist, J. Hara, J. T. Willie, C. T. Beuckmann, R. M. Chemelli, T. Sakurai, M. Yanagisawa, et al.
Orexin (Hypocretin) Neurons Contain Dynorphin
J. Neurosci., October 1, 2001; 21(19): RC168 - RC168.
[Abstract] [Full Text] [PDF]
M. N. Alam, H. Gong, T. Alam, R. Jaganath, D. McGinty, and R. Szymusiak
Sleep-waking discharge patterns of neurons recorded in the rat perifornical lateral hypothalamic area
J. Physiol., January 15, 2002; 538(2): 619 - 631.
[Abstract] [Full Text] [PDF]
|
|
|
|
 |
|